

Bernadette Anna Maria Heemskerk-Gen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7048783/publications.pdf>

Version: 2024-02-01

23
papers

976
citations

933447

10
h-index

677142

22
g-index

25
all docs

25
docs citations

25
times ranked

1766
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
2	Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. <i>International Journal of Cancer</i> , 2015, 136, 668-677.	5.1	158
3	Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic. <i>Annals of Surgical Oncology</i> , 2007, 14, 3335-3344.	1.5	138
4	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
5	Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 723-733.	2.5	111
6	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	6.2	39
7	The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers. <i>Cancer</i> , 2013, 119, 955-962.	4.1	31
8	Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 557-566.	2.5	19
9	Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?. <i>Cancers</i> , 2021, 13, 2506.	3.7	17
10	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16
11	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	5.0	15
12	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMONY Study). <i>JMIR Research Protocols</i> , 2021, 10, e24414.	1.0	9
13	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	6.4	9
14	Long-term outcomes of bilateral direct-to-implant breast reconstruction in women at high breast cancer risk. <i>Journal of Plastic Surgery and Hand Surgery</i> , 2018, 52, 245-252.	0.8	7
15	Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. <i>Breast</i> , 2022, 61, 98-107.	2.2	6
16	Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?. <i>Cancers</i> , 2021, 13, 2370.	3.7	4
17	Association of Risk-Reducing Surgery With Cancer Risks and Mortality in BRCA Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2695.	7.4	3
18	Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues” author's reply. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 253-254.	2.5	2

#	ARTICLE	IF	CITATIONS
19	The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer. <i>Breast</i> , 2020, 52, 102-109.	2.2	2
20	The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer. <i>Menopause</i> , 2021, Publish Ahead of Print, 1307-1312.	2.0	2
21	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	3.3	2
22	Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study. <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	1
23	Author Reply: Decision-Making Management of Women with a High Risk of Developing Breast and Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 1791-1792.	1.5	0